STOCK TITAN

Dräger receives Frost & Sullivan's 2024 Best Practices Company of the Year Award in global respiratory care

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Positive)
Tags
Rhea-AI Summary
Dräger receives Frost & Sullivan's 2024 Best Practices Company of the Year Award for its innovative approach in the global respiratory care devices industry. The company is recognized for its visionary strategies, customer impact, and commitment to offering cost-effective solutions that enhance patient safety and care.
Positive
  • None.
Negative
  • None.

Award criteria include visionary innovation, performance, and customer impact

TELFORD, Pa., Feb. 29, 2024 /PRNewswire/ -- Dräger, an international leader in medical and safety technologies, today announced that Frost & Sullivan has selected the company for its 2024 Best Practices Company of the Year Award in the global respiratory care devices industry. Frost & Sullivan's selection process involves identifying companies that consistently develop growth strategies based on a visionary understanding of the future and effectively address new challenges and opportunities employing best practices and strategic analytics across a value chain.

"Today's healthcare decision makers are looking beyond devices to determine the value a product brings to their critical care environments," said President and CEO for Draeger, Inc., Lothar Thielen. "This award validates Dräger's approach of combining best-in-class products, cost-effective accessories, and service solutions – which together deliver unmatched value to the hospitals we support."

Addressing hospital needs by offering easy-to-use and cost-conscious solutions
According to Utkarsha Soundankar, senior research analyst at Frost & Sullivan, "Dräger has become one of the leading respiratory device vendors for its enhanced clinical outcomes, product quality, long-term customer support, and ongoing education tools, all of which assist in offering patient safety and enhanced care."

Dräger developed its new Evita V600, V800 and Babylog VN800 ventilators based on customer requirements for improving patient safety, patient outcomes, and hospital workflow. These devices can provide various modes of ventilation – such as high-flow O2 therapy, non-invasive ventilation, and invasive ventilation modes – using the same accessories. This eliminates the need to use multiple devices for critically ill patients who require different types of respiratory support, thereby streamlining workflow and reducing equipment costs.

Providing visionary scenarios through mega trends
Frost & Sullivan salutes Dräger for introducing first-to-market solutions and continually investing in the development of new technologies. One such example is Dräger's research collaboration with STIMIT for the investigation of ventilator-induced diaphragmatic dystrophy (VIDD). STIMIT is developing non-invasive diaphragm stimulation for preserving diaphragm thickness. An FDA-approved clinical trial for this emerging technology began in January 2024.

Fostering excellent customer ownership and service experiences
Used by leading hospitals worldwide, Dräger's respiratory devices are clinically validated, with detailed consideration for the hospital's specific application. To support hospital infection control protocols, Dräger designs its devices with smooth services and minimal nooks that can harbor infectious agents. The company has also developed an extensive line of single-patient use and reusable valves.

Frost & Sullivan cites Dräger's best-in-class services, a network of over 3000 technicians, remote service, 24/7 hotline support, and exceptional service follow up. The company also offers webinars and training classes for healthcare facilities that want to manage their own programs.

Dräger has a strong leadership team and actively supports the respiratory care community. As of 2023, Dräger donated more than 150 ventilators to respiratory schools in the United States to train the next generation of therapists and will donate another 185 ventilators in 2024.

About Frost & Sullivan Best Practices Awards
For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, mega trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Disclaimer
Dräger is a leading international medical and safety technology company. Our products protect, support and save lives. Founded in 1889, Dräger generated global sales of around EUR 3 billion in 2022.

The Lübeck-based company is represented in more than 190 countries and employs more than 16,000 people worldwide. For more information, visit www.draeger.com

CONTACT: Laura Edwards, Tel. +1 215 565-5868, laura.edwards@draeger.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/drager-receives-frost--sullivans-2024-best-practices-company-of-the-year-award-in-global-respiratory-care-302075830.html

SOURCE Draeger

FAQ

What award did Dräger receive in 2024?

Dräger received Frost & Sullivan's 2024 Best Practices Company of the Year Award in the global respiratory care devices industry.

What are some key factors that led to Dräger receiving the award?

Dräger was recognized for its visionary strategies, customer impact, and commitment to offering cost-effective solutions that enhance patient safety and care.

What new ventilators did Dräger develop based on customer requirements?

Dräger developed the Evita V600, V800, and Babylog VN800 ventilators based on customer requirements for improving patient safety, outcomes, and hospital workflow.

What is Dräger's research collaboration with STIMIT focused on?

Dräger's research collaboration with STIMIT is focused on investigating ventilator-induced diaphragmatic dystrophy (VIDD) and developing non-invasive diaphragm stimulation for preserving diaphragm thickness.

How does Dräger support hospital infection control protocols?

Dräger designs its devices with smooth surfaces and minimal nooks to support hospital infection control protocols and has developed an extensive line of single-patient use and reusable valves.

What initiatives has Dräger taken to support the respiratory care community?

Dräger has donated ventilators to respiratory schools in the United States to train therapists and actively supports the respiratory care community.

DRAEGERWERK AG ORD

OTC:DGWPF

DGWPF Rankings

DGWPF Latest News

DGWPF Stock Data

880.90M
11.48M
71.62%
8.39%
Medical Devices
Healthcare
Link
United States of America
Lübeck